Literature DB >> 26290229

Blocking IGF Signaling in Adult Neurons Alleviates Alzheimer's Disease Pathology through Amyloid-β Clearance.

Géraldine Gontier1, Caroline George1, Zayna Chaker2, Martin Holzenberger3, Saba Aïd1.   

Abstract

Alzheimer's disease (AD) is a frequent and irreversible age-related neurodegeneration without efficient treatment. Experimental AD in mice responds positively to decreased insulin-like growth factor I (IGF-I) signaling, a pathway also implicated in aging. Here we aimed to protect the aging brain from devastating amyloid pathology by making specifically adult neurons resistant to IGF signaling. To achieve that, we knocked out neuronal IGF-1R during adulthood in APP/PS1 mice. We found that mutants exhibited improved spatial memory and reduced anxiety. Mutant brains displayed fewer amyloid plaques, less amyloid-β (Aβ), and diminished neuroinflammation. Surprisingly, adult neurons undergoing IGF-1R knock-out reduced their apical soma and developed leaner dendrites, indicative of remarkable structural plasticity entailing condensed forebrain neuroarchitecture. Neurons lacking IGF-1R in AD showed less accumulation of Aβ-containing autophagic vacuoles. At the same time, plasma Aβ levels were increased. Our data indicate that neuronal IGF-1R ablation, via preserved autophagic compartment and enhanced systemic elimination, offers lifelong protection from AD pathology by clearing toxic Aβ. Neuronal IGF-1R, and possibly other cell size-controlling pathways are promising targets for AD treatment. SIGNIFICANCE STATEMENT: We found compelling evidence in vivo that Alzheimer's disease (AD) progression is significantly delayed when insulin-like growth factor (IGF) signaling is blocked in adult neurons. To show that, we built a novel mouse model, combining inducible neuron-specific IGF-1R knock-out with AD transgenics. Analysis of the experimental AD phenotype revealed less abundant amyloid-β (Aβ) peptides, fewer plaques, and diminished neuroinflammation in mutants with inactivated IGF signaling, together with clearly preserved behavioral and memory performances. We present for the first time evidence that IGF signaling has profound effects on neuronal proteostasis and maintenance of cell morphology in vivo. Our results indicate in a model highly pertinent to translational research that neuronal IGF resistance may represent a pathophysiologically relevant mechanism of the brain for preventing Aβ accumulation.
Copyright © 2015 the authors 0270-6474/15/3511500-14$15.00/0.

Entities:  

Keywords:  Alzheimer's disease; amyloid-β; conditional mutagenesis; insulin-like growth factor; mouse model; neuron

Mesh:

Substances:

Year:  2015        PMID: 26290229      PMCID: PMC6605240          DOI: 10.1523/JNEUROSCI.0343-15.2015

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  62 in total

1.  IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice.

Authors:  Martin Holzenberger; Joëlle Dupont; Bertrand Ducos; Patricia Leneuve; Alain Géloën; Patrick C Even; Pascale Cervera; Yves Le Bouc
Journal:  Nature       Date:  2002-12-04       Impact factor: 49.962

2.  Serum insulin-like growth factor I regulates brain amyloid-beta levels.

Authors:  E Carro; J L Trejo; T Gomez-Isla; D LeRoith; I Torres-Aleman
Journal:  Nat Med       Date:  2002-11-04       Impact factor: 53.440

3.  Igf1 promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy.

Authors:  J Wang; J Zhou; C A Bondy
Journal:  FASEB J       Date:  1999-11       Impact factor: 5.191

4.  Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease.

Authors:  C H Kwon; X Zhu; J Zhang; L L Knoop; R Tharp; R J Smeyne; C G Eberhart; P C Burger; S J Baker
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

5.  Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease.

Authors:  S A Backman; V Stambolic; A Suzuki; J Haight; A Elia; J Pretorius; M S Tsao; P Shannon; B Bolon; G O Ivy; T W Mak
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

6.  Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?

Authors:  Eric Steen; Benjamin M Terry; Enrique J Rivera; Jennifer L Cannon; Thomas R Neely; Rose Tavares; X Julia Xu; Jack R Wands; Suzanne M de la Monte
Journal:  J Alzheimers Dis       Date:  2005-02       Impact factor: 4.472

7.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides.

Authors:  Milla Koistinaho; Suizhen Lin; Xin Wu; Michail Esterman; Deanna Koger; Jeffrey Hanson; Richard Higgs; Feng Liu; Seema Malkani; Kelly R Bales; Steven M Paul
Journal:  Nat Med       Date:  2004-06-13       Impact factor: 53.440

8.  Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice.

Authors:  Jun Wang; Heikki Tanila; Jukka Puoliväli; Inga Kadish; Thomas van Groen
Journal:  Neurobiol Dis       Date:  2003-12       Impact factor: 5.996

9.  Interleukin-6 deficiency increases blood volume without altering body composition in young mice.

Authors:  Hirobumi Gunji; Roderick A Little; Kouichi Hiraiwa
Journal:  Cytokine       Date:  2002-10-07       Impact factor: 3.861

10.  Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase.

Authors:  Joanna L Jankowsky; Daniel J Fadale; Jeffrey Anderson; Guilian M Xu; Victoria Gonzales; Nancy A Jenkins; Neal G Copeland; Michael K Lee; Linda H Younkin; Steven L Wagner; Steven G Younkin; David R Borchelt
Journal:  Hum Mol Genet       Date:  2003-11-25       Impact factor: 6.150

View more
  48 in total

1.  Adenovirus-Mediated Transduction of Insulin-Like Growth Factor 1 Protects Hippocampal Neurons from the Toxicity of Aβ Oligomers and Prevents Memory Loss in an Alzheimer Mouse Model.

Authors:  Maria Clara Selles; Juliana T S Fortuna; Maria F Zappa-Villar; Yasmin P R de Faria; Amanda S Souza; Claudia K Suemoto; Renata E P Leite; Roberta D Rodriguez; Lea T Grinberg; Paula C Reggiani; Sergio T Ferreira
Journal:  Mol Neurobiol       Date:  2019-11-23       Impact factor: 5.590

Review 2.  The effects of insulin and insulin-like growth factor I on amyloid precursor protein phosphorylation in in vitro and in vivo models of Alzheimer's disease.

Authors:  Bhumsoo Kim; Sarah E Elzinga; Rosemary E Henn; Lisa M McGinley; Eva L Feldman
Journal:  Neurobiol Dis       Date:  2019-07-23       Impact factor: 5.996

Review 3.  On the Run for Hippocampal Plasticity.

Authors:  C'iana Cooper; Hyo Youl Moon; Henriette van Praag
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

4.  Specific activation of mGlu2 induced IGF-1R transactivation in vitro through FAK phosphorylation.

Authors:  Yong-Jian Hu; Qian Sun; Wen-Hua Zhang; Yu-Jia Huo; Chan-Juan Xu; Jian-Feng Liu
Journal:  Acta Pharmacol Sin       Date:  2018-06-26       Impact factor: 6.150

5.  Circulating insulin-like growth factor 1 and insulin-like growth factor binding protein-3 level in Alzheimer's disease: a meta-analysis.

Authors:  Xiaohui Hu; Yan Yang; Daokai Gong
Journal:  Neurol Sci       Date:  2016-07-05       Impact factor: 3.307

Review 6.  The Somatotropic Axis in Human Aging: Framework for the Current State of Knowledge and Future Research.

Authors:  Sofiya Milman; Derek M Huffman; Nir Barzilai
Journal:  Cell Metab       Date:  2016-06-14       Impact factor: 27.287

7.  Insulin-like growth factor 1 receptor regulates hypothermia during calorie restriction.

Authors:  Rigo Cintron-Colon; Manuel Sanchez-Alavez; William Nguyen; Simone Mori; Ruben Gonzalez-Rivera; Tiffany Lien; Tamas Bartfai; Saba Aïd; Jean-Christophe François; Martin Holzenberger; Bruno Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-21       Impact factor: 11.205

8.  Atypical PKC, PKCλ/ι, activates β-secretase and increases Aβ1-40/42 and phospho-tau in mouse brain and isolated neuronal cells, and may link hyperinsulinemia and other aPKC activators to development of pathological and memory abnormalities in Alzheimer's disease.

Authors:  Mini P Sajan; Barbara C Hansen; Margaret G Higgs; C Ron Kahn; Ursula Braun; Michael Leitges; Collin R Park; David M Diamond; Robert V Farese
Journal:  Neurobiol Aging       Date:  2017-09-15       Impact factor: 4.673

9.  Central IGF-1 protects against features of cognitive and sensorimotor decline with aging in male mice.

Authors:  Gabriela E Farias Quipildor; Kai Mao; Zunju Hu; Ardijana Novaj; Min-Hui Cui; Maria Gulinello; Craig A Branch; Sriram Gubbi; Khushbu Patel; Douglas R Moellering; Stefano Tarantini; Tamas Kiss; Andriy Yabluchanskiy; Zoltan Ungvari; William E Sonntag; Derek M Huffman
Journal:  Geroscience       Date:  2019-05-10       Impact factor: 7.713

10.  Stress-altered synaptic plasticity and DAMP signaling in the hippocampus-PFC axis; elucidating the significance of IGF-1/IGF-1R/CaMKIIα expression in neural changes associated with a prolonged exposure therapy.

Authors:  Olalekan M Ogundele; Philip J Ebenezer; Charles C Lee; Joseph Francis
Journal:  Neuroscience       Date:  2017-04-27       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.